Summary
• PACS Group, Inc. shares rose 39% in pre-market trading to $23.41 following third-quarter earnings release.
• The company reported an EPS of $0.3182, missing estimates by approximately 30.8%, but demonstrated regulatory compliance by completing financial restatements.
• Analysts maintained a “Buy” rating and adjusted the target price to $32-$33, indicating confidence in PACS’ recovery.
PACS Group, Inc. (PACS) is experiencing a notable surge in pre-market trading, with shares climbing to $23.41, reflecting a 39% increase from the last close of $16.83. This significant price action follows the release of third-quarter financial results, which, despite a surprise miss on earnings estimates, has sparked renewed investor interest.
Earnings Spark Sharp Move
The catalyst for today’s move stems from PACS’ announcement regarding its third-quarter results released on November 19, 2025. The company reported an actual earnings per share (EPS) of $0.3182, falling short of analyst estimates of $0.46, which indicates a surprise of approximately -30.8%. However, the company highlighted that it has successfully completed its restatement of financials and is now current with its SEC obligations, suggesting a commitment to transparency and compliance that investors find positive.
The third-quarter performance follows a challenging previous quarter, where PACS reported an actual EPS of -$0.07 against an estimate of $0.47, highlighting an arc of improvement in operational stability despite the recent disappointment in estimates.
[chart type=’income-bar-chart’ value=’PACS’]
Regulatory Filings and Disclosures
In addition to the earnings report, PACS also filed an 8-K and a 10-K regarding its financial standing on the same date. These filings, accepted by the SEC, follow a prior announcement on November 17, indicating the company’s readiness to disclose its outstanding quarterly filings, further underpinning its regulatory compliance.
[chart type=’sec’ value=’PACS’]
Market and Technical Picture
Currently, PACS is trading at significant levels with a 52-week high of $299.47 and a low of $7.85, showcasing immense volatility. The 14-day relative strength index (RSI) stands impressively at 85.93, signaling potentially overbought conditions in the wake of the substantial price increase. The stock’s average volume over the past 10 days averages 6,804,646 shares, vastly exceeding the 3-month average of 1,510,178 shares, indicating heightened trading activity.
[chart type=’price’ value=’PACS’]
Analyst Sentiment
PACS has drawn favorable attention from analysts, with a maintained rating of “Buy” and a recent upgrade to “Outperform” from RBC Capital. The target price has been adjusted to between $32 and $33, reflecting growing confidence in the company’s recovery path and future performance potential.
With the latest update now reflected in trading, investors appear to be reassessing the company’s growth profile in light of its operational progress and improving compliance with SEC requirements.